MINNEAPOLIS, June 27, 2016 (GLOBE NEWSWIRE) -- Skyline Medical Inc. (NASDAQ:SKLN) (“Skyline” or
“the Company”), producer of the FDA-approved STREAMWAY System for automated, direct-to-drain medical fluid disposal, announces that
it has received ISO 13485:2003 certification for its STREAMWAY System. ISO certification is an internationally recognized
quality standard for medical devices that is awarded when an organization demonstrates its ability to provide medical devices and
related services that consistently meet customer and regulatory requirements applicable to medical devices and related services,
and is a requirement for medical device clearance in Canada, the EU and a majority of other countries that require products meet EU
safety, health and environmental requirements.
“This is an important step to penetrating a broader market for the STREAMWAY System,” said Carl Schwartz,
D.D.S., interim chief executive officer of Skyline Medical. “We plan to apply to Health Canada for marketing authorization in the
coming weeks. We believe that this ISO Certification, along with our U.S. Food and Drug Administration 510(k) clearance, should
result in the grant of a Medical Device License to sell the STREAMWAY System and related disposable products in Canada by the end
of the summer.”
“The process for obtaining ISO Certification is quite rigorous, and we are very excited to receive it.
Skyline has proven that its design, manufacturing, quality systems along with STREAMWAY’s value to patients meet the highest
standards,” commented Dave Johnson, chief operating officer of Skyline Medical.
About the STREAMWAY System
Skyline Medical's revolutionary, FDA-cleared STREAMWAY System is the first true direct-to-drain fluid disposal system designed
specifically for medical applications, such as radiology, endoscopy, urology and cystoscopy procedures. It connects directly to a
facility's plumbing system to automate the collection, measurement and disposal of waste fluids, and minimizes human intervention
for better safety while improving compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency
safety guidelines. It also provides unlimited capacity for increased efficiency in the operating room, which leads to greater
profitability. The STREAMWAY eliminates canisters to reduce overhead costs and provides greater environmental stewardship by
helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the
U.S.
About Skyline Medical Inc.
Skyline Medical Inc. produces a fully automated, patented, FDA-cleared, waste fluid disposal system that virtually eliminates staff
exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual
fluid handling methods — which require hand carrying and emptying filled fluid canisters — present an exposure risk and potential
liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is
designed to: 1) reduce overhead costs to hospitals and surgical centers, 2) improve compliance with OSHA and other regulatory
agency safety guidelines, 3) improve efficiency in the operating room, and radiology and endoscopy departments — leading to greater
profitability, and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially
disease-infected canisters that go into landfills annually in the United States. For additional information, please visit www.skylinemedical.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements
made herein. Such risks and uncertainties include, among other things, current negative operating cash flows and a need for
additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include
onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and
ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not
accepted by our potential customers, it is unlikely that we will ever become profitable, adverse economic conditions; adverse
results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain
qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the
proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and
patent applications necessary to develop products; the Company's ability to implement its long range business plan for various
applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution
partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to
applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time
to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to
be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent
reports and other filings at www.sec.gov.
Contact: Investors LHA Kim Sutton Golodetz (212) 838-3777 kgolodetz@lhai.com
